Compare Bristol-Myers Squibb Co (BMY) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs NetApp Inc. — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while NetApp Inc. trades at $175.12 (market cap $34.20B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.4× NetApp Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | NTAP | |
|---|---|---|
Market Cap | $116.30B | $34.20B |
Sector | Health | Technology |
52-Week High | $62.37 | $181.08 |
52-Week Low | $42.60 | $94.11 |
Enterprise Value | $152.24B | $33.35B |
Dividend Yield | 4.42% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
NetApp (NTAP) trades at $163.93, down 2.93% on the day, but maintains a bullish technical stance with strong moving averages and support near $162. The company demonstrates robust fundamentals with a 70.74% gross margin and consistent earnings beats, including Q1 2026 EPS of $2.43 versus $2.27 expected. Recent news highlights AI-driven growth opportunities, such as StorageGRID 12.1 enhancements for AI workloads announced on June 23, 2026.
Outlook remains positive with analyst consensus target at $167.45, offering modest upside. Key opportunities include enterprise AI demand and all-flash storage adoption, while risks involve competitive pressures and debt levels rising to 29.89% of assets. The stock's valuation at a P/E of 25.82 warrants monitoring amid sector comparisons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
